PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16104681

Nuchal translucency-based Down syndrome screening: barriers to implementation.

Fergal D Malone
View original source ↗Export metadata ↓

Abstract

Nuchal translucency sonography represents an important step forward in screening for Down syndrome. It is likely that a range of screening programs that rely on nuchal translucency sonography will become popular for general population screening. However, a number of practical implementation issues remain to be resolved before widespread utilization of this technique can be endorsed. This paper addresses some of these issues, including sonographer training, standardized nuchal translucency sonography protocol, ongoing nuchal translucency quality assurance programs, how to interpret Down syndrome risk, availability of first trimester diagnosis, and how to combine screening tests across different gestational ages.

Explore related subjects

Down SyndromeFemaleFetal DiseasesHealth PersonnelHumansNuchal Translucency MeasurementPregnancyPregnancy Trimester, FirstJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Fergal D Malone. 2005. Nuchal translucency-based Down syndrome screening: barriers to implementation.. https://doi.org/10.1053/j.semperi.2005.05.002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Fasudil induces anti-inflammatory transcriptomic changes and increased proliferation in human trisomy 21 neural progenitor cells.

Down syndrome (DS) results from trisomy for human chromosome 21 and is the most frequent genetic cause of intellectual disability. No effective treatments currently exist that improve neurodevelopment and cognition. Atypical brain development in individuals with DS is apparent before birth, which suggests that the optimal time to begin administration of therapies is prenatally. Human neural progenitor cell (NPC) cultures provide a tractable in vitro model system to examine the effects of trisomy 21 (T21) on neurodevelopment and to measure the effects of pharmacological interventions. Here, we report the results of preclinical studies evaluating 24 candidate therapies. RNA sequencing analyses found that euploid and T21 NPCs showed different transcriptomic responses to five candidate pharmacotherapies. The Rho-associated coiled-coil kinase inhibitor fasudil increased proliferation of T21 NPCs, reduced expression of inflammatory pathway genes in T21 NPCs, and reduced markers of inflammation in LPS-stimulated microglial model systems. These results demonstrate that fasudil can alter multiple T21-associated abnormalities in a beneficial manner, suggesting that fasudil warrants further study as a candidate prenatal pharmacotherapy for DS.

Down Syndrome↗